Gilead plans European trial of twice-yearly HIV PrEP drug

Gilead Sciences has said it will soon start a clinical trial in Europe of its twice-yearly HIV injection Sunlenca for pre-exposure prophylaxis (PrEP), a potential successor to its big-selling Truvada and Descovy brands, which need to be dosed every day.